NovaTarg Therapeutics is a privately owned pharmaceutical company that has a leadership team experienced in drug discovery which has established a novel approach to the discovery of tissue targeted medicines.
The NovaTarg approach comprises 2 principal elements:
1. Transporter Dependent Drug Delivery (T3D)
2. A focus on the discovery and development of AMP-activated kinase (AMPK) activators
Our approach is to design and synthesize small molecules that utilize specific transporters that allow our drugs to selectively enter target cells. Activation of AMPK in a tissue selective manner provides improved efficacy and safety for the treatment of human cancers (ovarian and hepatocellular), type 2 diabetes (T2D) and hepatitis C (HCV).
Intellectual property rights covering our first drug candidates have been filed.